Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Peptide-metal chelate conjugates|
|Abstract:||This invention relates to diagnostic and radiodiagnostic agents, including radiolabeled scintigraphic imaging agents, and therapeutic and radiotherapeutic agents. The invention provides such agents and reagents for preparing such agents, and methods for producing and using such reagents. Specifically, the invention provides radiolabeled imaging agents and non-radioactively labeled imaging agents for imaging sites in a mammalian body and reagents for preparing these imaging agents. The invention also provides radiolabeled therapeutic agents, as well as non-radioactively labeled therapeutic agents, and reagents and methods for preparing these agents. The agents and reagents provided comprise a specific binding peptide, covalently linked to a metal ion-complexing moiety. Reagents, methods and kits for making such reagents, methods for labeling such reagents, and methods for using such labeled reagents are provided.|
|Inventor(s):||Dean; Richard T. (Bedford, NH)|
|Assignee:||Diatide, Inc. (Londonderry, NH)|
|Filing Date:||Mar 13, 1998|
|Claims:||1. A pharmaceutical composition comprising: |
a) a somatostatin receptor-binding peptide having a formula:
X is a metal ion complexing moiety having formula
B is a thiol-containing moiety that is cysteine, homocysteine, isocysteine, or penicillamine;
(amino acid).sub.n and (amino acid).sub.m are each independently any primary .alpha.- or .beta.-amino acid that does not comprise a thiol group;
Z is --OH or --NH.sub.2 ;
n is an integer between 2 and 5; and
m is an integer between 0 and 5; and
b) a pharmaceutically acceptable carrier.
2. The composition of claim 1, further comprising a metal ion bound to the metal ion complexing moiety.
3. The composition of claim 2, wherein the metal ion is selected from the group consisting of a radioactive metal ion, a paramagnetic metal ion, a nonradioactive metal ion, and a superparamagnetic particle.
4. The composition of claim 3, wherein the metal ion is a radioactive metal ion selected from the group consisting of a beta-particle emitting metal ion, a conversion electron emitting metal ion, and a gamma emitting metal ion.
5. The composition of claim 4, wherein the radioactive metal ion is a beta-particle emitting metal ion selected from the group consisting of rhenium-186 and rhenium-188.
6. The composition of claim 4, wherein the radioactive metal ion is a conversion emitting metal ion.
7. The composition of claim 6, wherein the metal ion is tin-117m.
8. The composition of claim 4, wherein the radioactive metal ion is a gamma emitting metal ion selected from the group consisting of iodine-125, iodine-131, and astatine-211.
9. The composition of claim 3, wherein the metal ion is a paramagnetic metal ion selected from the group consisting of iron and copper.
10. The composition of claim 3, wherein the metal ion is a nonradioactive metal ion selected from the group consisting of copper, zinc, tin, and rhenium.